Cargando…

Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission

AIM: While evidence‐based antidepressant treatment is available for major depressive disorder, standard approaches for discontinuation of antidepressants after remission have not yet been established. Decision aids are structured clinical tools that facilitate shared decision‐making between patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoki, Yumi, Takaesu, Yoshikazu, Baba, Hajime, Iga, Jun‐ichi, Hori, Hikaru, Inoue, Takeshi, Mishima, Kazuo, Tajika, Aran, Kato, Masaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515698/
https://www.ncbi.nlm.nih.gov/pubmed/35775506
http://dx.doi.org/10.1002/npr2.12269
_version_ 1784798543264874496
author Aoki, Yumi
Takaesu, Yoshikazu
Baba, Hajime
Iga, Jun‐ichi
Hori, Hikaru
Inoue, Takeshi
Mishima, Kazuo
Tajika, Aran
Kato, Masaki
author_facet Aoki, Yumi
Takaesu, Yoshikazu
Baba, Hajime
Iga, Jun‐ichi
Hori, Hikaru
Inoue, Takeshi
Mishima, Kazuo
Tajika, Aran
Kato, Masaki
author_sort Aoki, Yumi
collection PubMed
description AIM: While evidence‐based antidepressant treatment is available for major depressive disorder, standard approaches for discontinuation of antidepressants after remission have not yet been established. Decision aids are structured clinical tools that facilitate shared decision‐making between patients and healthcare providers. This study aimed to describe the development process and acceptability of decision aids for major depressive disorder following discontinuation of antidepressant treatment after remission. METHODS: We systematically developed a decision aids according to the International Patient Decision Aid Standards. First, a decision aids prototype was created using the results of a systematic review and meta‐analysis previously conducted to identify the consequences of continuing and discontinuing antidepressant treatment. Second, a mixed‐methods questionnaire (alpha acceptability testing) was administered to patients and healthcare providers to improve the decision aids prototype and develop it into a final version acceptable for clinical settings. RESULTS: Our decision aids consisted of a description of major depressive disorder, the option to continue or discontinue antidepressant treatment, the advantages and disadvantages of each option, the consequences of each option, and value clarification exercises for each option. The patients (n = 22) reported that the decision aids had acceptable language (91%), adequate information (91%), and a well‐balanced presentation (95%). Healthcare providers (n = 20) provided favorable feedback. The final decision aids fulfilled all six International Patient Decision Aid Standards qualifying criteria. CONCLUSION: We successfully developed a decision aids for discontinuation of antidepressant treatment after remission, which could be used during the shared decision‐making process. Further studies are needed to verify the effects of using the decision aids during the shared decision‐making process.
format Online
Article
Text
id pubmed-9515698
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95156982022-10-05 Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission Aoki, Yumi Takaesu, Yoshikazu Baba, Hajime Iga, Jun‐ichi Hori, Hikaru Inoue, Takeshi Mishima, Kazuo Tajika, Aran Kato, Masaki Neuropsychopharmacol Rep Original Articles AIM: While evidence‐based antidepressant treatment is available for major depressive disorder, standard approaches for discontinuation of antidepressants after remission have not yet been established. Decision aids are structured clinical tools that facilitate shared decision‐making between patients and healthcare providers. This study aimed to describe the development process and acceptability of decision aids for major depressive disorder following discontinuation of antidepressant treatment after remission. METHODS: We systematically developed a decision aids according to the International Patient Decision Aid Standards. First, a decision aids prototype was created using the results of a systematic review and meta‐analysis previously conducted to identify the consequences of continuing and discontinuing antidepressant treatment. Second, a mixed‐methods questionnaire (alpha acceptability testing) was administered to patients and healthcare providers to improve the decision aids prototype and develop it into a final version acceptable for clinical settings. RESULTS: Our decision aids consisted of a description of major depressive disorder, the option to continue or discontinue antidepressant treatment, the advantages and disadvantages of each option, the consequences of each option, and value clarification exercises for each option. The patients (n = 22) reported that the decision aids had acceptable language (91%), adequate information (91%), and a well‐balanced presentation (95%). Healthcare providers (n = 20) provided favorable feedback. The final decision aids fulfilled all six International Patient Decision Aid Standards qualifying criteria. CONCLUSION: We successfully developed a decision aids for discontinuation of antidepressant treatment after remission, which could be used during the shared decision‐making process. Further studies are needed to verify the effects of using the decision aids during the shared decision‐making process. John Wiley and Sons Inc. 2022-07-01 /pmc/articles/PMC9515698/ /pubmed/35775506 http://dx.doi.org/10.1002/npr2.12269 Text en © 2022 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Aoki, Yumi
Takaesu, Yoshikazu
Baba, Hajime
Iga, Jun‐ichi
Hori, Hikaru
Inoue, Takeshi
Mishima, Kazuo
Tajika, Aran
Kato, Masaki
Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission
title Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission
title_full Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission
title_fullStr Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission
title_full_unstemmed Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission
title_short Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission
title_sort development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515698/
https://www.ncbi.nlm.nih.gov/pubmed/35775506
http://dx.doi.org/10.1002/npr2.12269
work_keys_str_mv AT aokiyumi developmentandacceptabilityofadecisionaidformajordepressivedisorderconsideringdiscontinuationofantidepressanttreatmentafterremission
AT takaesuyoshikazu developmentandacceptabilityofadecisionaidformajordepressivedisorderconsideringdiscontinuationofantidepressanttreatmentafterremission
AT babahajime developmentandacceptabilityofadecisionaidformajordepressivedisorderconsideringdiscontinuationofantidepressanttreatmentafterremission
AT igajunichi developmentandacceptabilityofadecisionaidformajordepressivedisorderconsideringdiscontinuationofantidepressanttreatmentafterremission
AT horihikaru developmentandacceptabilityofadecisionaidformajordepressivedisorderconsideringdiscontinuationofantidepressanttreatmentafterremission
AT inouetakeshi developmentandacceptabilityofadecisionaidformajordepressivedisorderconsideringdiscontinuationofantidepressanttreatmentafterremission
AT mishimakazuo developmentandacceptabilityofadecisionaidformajordepressivedisorderconsideringdiscontinuationofantidepressanttreatmentafterremission
AT tajikaaran developmentandacceptabilityofadecisionaidformajordepressivedisorderconsideringdiscontinuationofantidepressanttreatmentafterremission
AT katomasaki developmentandacceptabilityofadecisionaidformajordepressivedisorderconsideringdiscontinuationofantidepressanttreatmentafterremission